Interaction of macrocyclic lactones with P-glycoprotein: Structure-affinity relationship

被引:148
作者
Lespine, Anne
Martin, Solenne
Dupuy, Jacques
Roulet, Alain
Pineau, Thierry
Orlowski, Stephane
Alvinerie, Michel
机构
[1] INRA, Lab Pharmacol & Toxicol, UR66, F-31931 Toulouse 9, France
[2] CEA Saclay, CNRS, SBFM, DBJC, F-91191 Gif Sur Yvette, France
[3] CEA Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France
关键词
P-glycoprotein; macrocyclic lactones; structure-affinity; antiparasitic therapy; drug transport; ATPase;
D O I
10.1016/j.ejps.2006.10.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P-glycoprotein (P-gp) is involved in the ATP-dependant cellular efflux of a large number of drugs including ivermectin, a macrocyclic lactone (ML) endectocide, widely used in livestock and human antiparasitic therapy The interactions of P-gp with ivermectin and other MLs were studied. in a first approach, the ability of ivermectin (IVM), eprinomectin (EPR), abamectin (ABA), doramectin (DOR), selamectin (SEL), or moxidectin (MOX) to inhibit the rhodamine123 efflux was measured in recombinant cells overexpressing P-gp. Then, the influence of these compounds on the P-gp ATPase activity was tested on membrane vesicles prepared from fibroblasts overexpressing P-gp. All the MLs tested increased the intracellular rhodamine123. However, the potency of MOX to inhibit P-gp function was 10 times lower than the other MLs. They all inhibited the basal and decreased the verapamil-stimulated P-gp ATPase activity. But SEL and MOX were less potent than the other MLs when competing with verapamil. According to the structural specificity of SEL and MOX, we conclude that the integrity of the sugar moiety is determinant to achieve the optimal interaction of macrocyclic lactones with P-gp. The structure-affinity relationship for interaction with P-gp is important information for improving ML bioavailability and reversal of multidrug resistance (MDR). (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:84 / 94
页数:11
相关论文
共 50 条
[1]   Pharmacokinetics of eprinomectin in plasma and milk following topical administration to lactating dairy cattle [J].
Alvinerie, M ;
Sutra, JF ;
Galtier, P ;
Mage, C .
RESEARCH IN VETERINARY SCIENCE, 1999, 67 (03) :229-232
[2]   Enhanced absorption of pour-on ivermectin formulation in rats by co-administration of the multidrug-resistant-reversing agent verapamil [J].
Alvinerie, M ;
Dupuy, J ;
Eeckhoutte, C ;
Sutra, JF .
PARASITOLOGY RESEARCH, 1999, 85 (11) :920-922
[3]   Macrocyclic lactones: distribution in plasma lipoproteins of several animal species including humans [J].
Bassissi, MF ;
Alvinerie, M ;
Lespine, A .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY, 2004, 138 (04) :437-444
[4]  
BIEDLER JL, 1970, CANCER RES, V30, P1174
[5]   The role of multidrug, transporters in drug availability, metabolism and toxicity [J].
Bodó, A ;
Bakos, E ;
Szeri, F ;
Váradi, A ;
Sarkadi, B .
TOXICOLOGY LETTERS, 2003, 140 :133-143
[6]   The multidrug resistance protein family [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1999, 1461 (02) :347-357
[7]   The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans [J].
Cotreau, MM ;
Warren, S ;
Ryan, JL ;
Fleckenstein, L ;
Vanapalli, SR ;
Brown, KR ;
Rock, D ;
Chen, CY ;
Schwertschlag, US .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (10) :1108-1115
[8]   The effects of body composition on the pharmacokinetics of subcutaneously injected ivermectin and moxidectin in pigs [J].
Craven, J ;
Bjorn, H ;
Hennessy, DR ;
Friis, C .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2002, 25 (03) :227-232
[9]   The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor [J].
Didier, A ;
Loor, F .
ANTI-CANCER DRUGS, 1996, 7 (07) :745-751
[10]   Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin [J].
Dupuy, J ;
Larrieu, G ;
Sutra, JF ;
Lespine, A ;
Alvinerie, M .
VETERINARY PARASITOLOGY, 2003, 112 (04) :337-347